These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 9111826

  • 1. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
    Meffert H, Bräutigam M, Färber L, Weidinger G.
    Acta Derm Venereol; 1997 Mar; 77(2):137-41. PubMed ID: 9111826
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
    Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE, Sirolimus European Psoriasis Study Group.
    Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
    [Abstract] [Full Text] [Related]

  • 3. Efficacious treatment of psoriasis with low-dose and intermittent cyclosporin microemulsion therapy.
    Ito T, Furukawa F, Iwatsuki K, Matsue H, Shimada S, Takigawa M, Tokura Y.
    J Dermatol; 2014 May; 41(5):377-81. PubMed ID: 24628433
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
    Ieiri I, Nakayama J, Murakami H, Hori Y, Higuchi S.
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
    [Abstract] [Full Text] [Related]

  • 7. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
    Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF, Multi-Centre Investigator Group.
    Br J Dermatol; 2005 Jun; 152(6):1219-27. PubMed ID: 15948985
    [Abstract] [Full Text] [Related]

  • 8. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 13. Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral).
    Salek MS, Finlay AY, Lewis JJ, Sumner MI.
    Qual Life Res; 2004 Feb; 13(1):91-5. PubMed ID: 15058791
    [Abstract] [Full Text] [Related]

  • 14. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis.
    Erkko P, Granlund H, Remitz A, Rosen K, Mobacken H, Lindelöf B, Reitamo S.
    Br J Dermatol; 1998 Dec; 139(6):997-1004. PubMed ID: 9990362
    [Abstract] [Full Text] [Related]

  • 15. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC, Mourellou O, Avgoustinaki N, Papakonstantinou M, Karakatsanis G, Katsambas A.
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
    Hashizume H, Ito T, Yagi H, Takigawa M, Kageyama H, Furukawa F, Hata M, Shirahama S, Tanaka M, Higashishiba T, Machida H, Tsushima T, Matsushita K.
    J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
    [Abstract] [Full Text] [Related]

  • 17. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
    Berth-Jones J, Henderson CA, Munro CS, Rogers S, Chalmers RJ, Boffa MJ, Norris PG, Friedmann PS, Graham-Brown RA, Dowd PM, Marks R, Sumner MJ.
    Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
    [Abstract] [Full Text] [Related]

  • 18. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment.
    Chow C, Simpson MJ, Luger TA, Chubb H, Ellis CN.
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1406-14. PubMed ID: 25917315
    [Abstract] [Full Text] [Related]

  • 19. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
    Dermatology; 1993 Jul; 187 Suppl 1():30-7. PubMed ID: 8369577
    [Abstract] [Full Text] [Related]

  • 20. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.
    Ho VC, Griffiths CE, Albrecht G, Vanaclocha F, León-Dorantes G, Atakan N, Reitamo S, Ohannesson A, Mørk NJ, Clarke P, Pfister P, Paul C.
    Br J Dermatol; 1999 Aug; 141(2):283-91. PubMed ID: 10468801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.